Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Renews Call to Ensure Stable Supply System to Prep for COVID Outbreak
July 25, 2024
- Japan Logs 10th Consecutive Year of Decrease in Drug Reps, Hefty Dip in 2023
July 25, 2024
- Off-Year Scheme Drifting Away from Four-Minister Deal: JPMA Exec
July 19, 2024
- Cancel or Postpone FY2025 Revision, or Scrap Off-Year Scheme: New JPA Chief
July 19, 2024
- FIRM Hails Guidance on Conditional Approval of Regenerative Medicines
July 17, 2024
- EFPIA Japan Names Yoshiaki Aono as Director General
July 11, 2024
- Labor Union Group Urges Abolishment of Off-Year Price Revisions
June 27, 2024
- Japan Digital Health Alliance Keen to Boost Ties with Overseas Organizations
June 21, 2024
- JGA to Establish Study Group on Generic Industry Realignment
June 21, 2024
- Majority of Candidates for G1 Withdrawal Scheme Not Able to Exit Market: FPMAJ Survey
June 17, 2024
- FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
June 17, 2024
- EFPIA Japan Issues New Proposal on HTA, Calls for Transparency
June 10, 2024
- 135 Meds Still in Lag/Loss State in Japan, JPMA Task Force Revving Up Fight
June 5, 2024
- JPMA Pushing Industry-Academia Consortia in Non-Competitive Drug Discovery Fields
June 5, 2024
- JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
- New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
- JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
- Policymakers Prod for Industry’s Concrete Actions Toward Eliminating Drug Loss
April 24, 2024
- Govt Should Buy Up Domestic Antibiotic APIs, Cost 5-8 Times Higher: Industry Official
April 24, 2024
- JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…